Interdepartmental Division of Critical Care Medicine, University of Toronto, Toronto, ON, Canada.
Department of Medicine, University of Toronto, Toronto, ON, Canada.
BMJ. 2022 May 4;377:e068723. doi: 10.1136/bmj-2021-068723.
To estimate the effect of extracorporeal membrane oxygenation (ECMO) compared with conventional mechanical ventilation on outcomes of patients with covid-19 associated respiratory failure.
Observational study.
30 countries across five continents, 3 January 2020 to 29 August 2021.
7345 adults admitted to the intensive care unit with clinically suspected or laboratory confirmed SARS-CoV-2 infection.
ECMO in patients with a partial pressure of arterial oxygen to fraction of inspired oxygen (PaO/FiO) ratio <80 mm Hg compared with conventional mechanical ventilation without ECMO.
The primary outcome was hospital mortality within 60 days of admission to the intensive care unit. Adherence adjusted estimates were calculated using marginal structural models with inverse probability weighting, accounting for competing events and for baseline and time varying confounding.
844 of 7345 eligible patients (11.5%) received ECMO at any time point during follow-up. Adherence adjusted mortality was 26.0% (95% confidence interval 24.5% to 27.5%) for a treatment strategy that included ECMO if the PaO/FiO ratio decreased <80 mm Hg compared with 33.2% (31.8% to 34.6%) had patients received conventional treatment without ECMO (risk difference -7.1%, 95% confidence interval -8.2% to -6.1%; risk ratio 0.78, 95% confidence interval 0.75 to 0.82). In secondary analyses, ECMO was most effective in patients aged <65 years and with a PaO/FiO <80 mm Hg or with driving pressures >15 cmHO during the first 10 days of mechanical ventilation.
ECMO was associated with a reduction in mortality in selected adults with covid-19 associated respiratory failure. Age, severity of hypoxaemia, and duration and intensity of mechanical ventilation were found to be modifiers of treatment effectiveness and should be considered when deciding to initiate ECMO in patients with covid-19.
评估体外膜肺氧合(ECMO)与常规机械通气相比对 COVID-19 相关呼吸衰竭患者结局的影响。
观察性研究。
2020 年 1 月 3 日至 2021 年 8 月 29 日,五大洲 30 个国家。
7345 名因疑似或实验室确诊 SARS-CoV-2 感染而入住重症监护病房的成年人。
与未行 ECMO 的常规机械通气相比,对动脉血氧分压与吸入氧分数(PaO/FiO)比值<80mmHg 的患者行 ECMO。
主要结局为重症监护病房入院后 60 天内的院内死亡率。采用边际结构模型和逆概率加权进行调整后估计,同时考虑竞争事件和基线及随时间变化的混杂因素。
在随访期间,7345 名符合条件的患者中有 844 名(11.5%)在任何时间点接受 ECMO。如果 PaO/FiO 比值<80mmHg 时采用 ECMO 的治疗策略,调整后的死亡率为 26.0%(95%置信区间为 24.5%至 27.5%),而接受常规治疗未行 ECMO 的死亡率为 33.2%(31.8%至 34.6%)(差异风险-7.1%,95%置信区间-8.2%至-6.1%;风险比 0.78,95%置信区间 0.75 至 0.82)。在次要分析中,在年龄<65 岁、PaO/FiO<80mmHg 或机械通气最初 10 天内驱动压>15cmHO 的患者中,ECMO 最有效。
在选定的 COVID-19 相关呼吸衰竭成人患者中,ECMO 与死亡率降低相关。年龄、低氧血症严重程度、机械通气持续时间和强度被发现是治疗效果的调节剂,在决定对 COVID-19 患者开始 ECMO 时应考虑这些因素。